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Background: Cervical cancer is one of the common gynecological malignancies with a high recurrence rate after
surgery. This study aimed to analyze the clinicopathological risk factors for recurrence after the surgical treatment of
cervical cancer and provide the basis for the prevention of recurrence and an improvement of prognosis.
Methods: A total of 424 cervical cancer cases between 1 January 1998 and 31 December 2011 undergoing surgical
treatment were studied retrospectively, of which 23 cases had recurrences. Relevant recurrence risk factors were
evaluated by univariate and multivariate analyses between recurrence group and non-recurrence group.
Results: Using univariate analysis, tumor differentiation, clinical stage, pelvic lymph node metastasis, postoperative
radiotherapy and postoperative chemotherapy were related to recurrence of cervical cancer. Multivariate COX
model analysis revealed that pelvic lymph node metastasis and postoperative chemotherapy had an impact on
recurrence rate. Moderately and highly differentiated tumor, advanced clinical stage, and positive pelvic lymph
nodes indicated a high recurrence rate of cervical cancer. Postoperative chemotherapy and radiotherapy can
effectively reduce the recurrence rate.
Conclusions: In conclusion, cervical lymph node metastasis and postoperative chemotherapy are two independent
factors for recurrence of cervical cancer after radical surgery.
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Cervical cancer is one of the common gynecological ma-
lignancies, with nearly 500,000 women developing the
disease each year worldwide [1]. Cervical cancer staging
generally runs from stage I, which is non-invasive, to
stage IV, in which the carcinoma has extended beyond
the true pelvis or has involved (biopsy proven) the
mucosa of the bladder or rectum, based on the Inter-
national Federation of Gynecology and Obstetrics
(FIGO) stage system [2]. Most women with early-stage
tumors can be cured by radical surgery. However, the
local tumor recurrence rate after radical surgery is up to
30% [3], and recurrence has become the main reason for
poor prognosis and a decreased survival rate.* Correspondence: huali-wang@126.com
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reproduction in any medium, provided the orRecently, though the application of surgery and adju-
vant therapy, early cervical cancer patients have a high
survival rate, especially for type Ib and IIa patients, with
the 5-year survival rate up to about 75 to 90% [4]. Those
with a large cervical lesion or positive pelvic lymph
nodes are usually treated with a combination of radio-
therapy with concomitant chemotherapy. In the last two
decades, several studies have shown that neoadjuvant
chemotherapy followed by radical hysterectomy is able
to obtain very satisfactory results in locally advanced
cervical cancer [5]. However, not much is known about
whether neoadjuvant chemotherapy, including preopera-
tive and postoperative therapy, can improve the recur-
rence rate of cervical cancer. In addition, cervical cancer
recurrence can be affected by many factors, such as
clinical stage, histological type, histological grade, treat-
ment method, self-status, and others [6,7]. Evaluating
these factors and looking for an effective treatment totd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.wjso.com/content/11/1/301improve the recurrence rate has become a hot topic for
gynecologic oncology. In this study, we aimed to find out
the clinical and pathological risk factors for cervical cancer
recurrence through retrospective analysis of 424 cervical
cancer patients undergoing radical hysterectomy.
Methods
Patients
A total of 424 women admitted to The Second Hospital of
Shandong University from 1 January 1998 to 31 December
2011 were included in this study. According to the FIGO
classification, there were 127 cases with stage IA, 97 cases
with stage IB (15 with stage IB1 and 82 with stage IB2),
112 cases with stage IIA and 88 cases with stage IIB
cancer. This study was approved by the Ethics Committee
of The Second Hospital of Shandong University and for-
mal informed consent was obtained from the patients.
Preoperative treatment
The patients with stage IB2, IIA or IIB carcinoma were
subjected to neoadjuvant therapy since their tumor
diameters were larger than 4 cm and good outcomes
may not have been available by direct surgical treatment.
Finally, 139 of 282 cases were treated with neoadjuvant
chemotherapy or radiotherapy preoperatively (Table 1).
The following neoadjuvant chemotherapy schemes were
used: i) didecyl phthalate (DDP) 20 mg/m2 (first 5 days) +
5-fluorouracil (5-FU) 0.75 g/m2 (first 5 days); ii) DDP
50 mg/m2 (first day) + bleomycin (BLM) 25 mg/m2 (first
3 days) + vincristine (VCR) 1 mg/m2 (first day) +mitomy-
cin (MMC) 10 mg/m2 (first day); and iii) DDP 50 mg/m2
(first day) + BLM 25 mg/m2 (first 3 days) + VCR 1 mg/m2
(first day). There were 18, 13 and 57 patients received
the first, second and third scheme of the neoadjuvant
chemotherapy, respectively. A cobalt 60 machine (AECL,
Canada) or 8 MeV medical linear accelerators (siemens,
Germany) were used for radiation therapy. The whole
pelvis was irradiated based on the anteroposterior view
with an area of 13 to 15 cm× 15 to 18 cm. The radiation
treatment was performed five times a week with a dosageTable 1 Number of patients treated with different
approaches
Different approaches Number
Preoperative treatment Neoadjuvant chemotherapy 88
Radiotherapy 51
None 285
Surgical treatment Abdominal surgery 328
Laparoscopic surgery 96
Postoperative treatment Chemotherapy 182
Radiotherapy 179
None 63of 1.8 to 2 Gy. The dose was then increased to 25 to 30 Gy,
two to three times a week, with the bladder and rectum
blocked by a 3 to 4 cm × 13 to 15 cm lead plate. Iridium-
192 intracavitary brachytherapy combined with pelvic
external radiation was then applied; the radiation dose of
iridium-192 intracavitary brachytherapy was 6 to 7 Gy each
time with a total dose of 30 to 42 Gy every week. The pre-
operative radiotherapy was finished within 6 to 8 weeks.
Surgical treatment
All the patients were treated by radical hysterectomy
and pelvic lymphadenectomy. Among them, 328 cases
were treated with abdominal surgery and the other 96
cases with laparoscopic surgery (Table 1).
Postoperative treatment
Patients with deep muscular involvement, vascular invasion
or a tumor diameter larger than 4 cm received two to four cy-
cles of chemotherapy (DDP + 5-FU) for 7 to 10 days after
surgery, while patients with two of above conditions were
treated with radiotherapy. If a positive lymph node, positive
surgical margin or paracervical involvement occurred, radio-
therapy was also considered. A total of 182 of 246 cases
underwent chemotherapy and 179 of 256 cases received
whole pelvic external radiation within 1month (Table 1).
The numbers of patients treated with the different
approaches are summarized in Table 1.
Follow-up
All cases were followed up by letter and telephone. The
follow-up time varied from a minimum of 2 months to a
maximum of 165 months.
Statistical analysis
SPSS 13.0 software (SPSS Inc., Chicago, IL, USA) was
used for statistical analysis. Eight clinicopathological fac-
tors that may be related to the recurrence of cervical
cancer were used for analysis. The recurrence time was
calculated from the day of surgery to the last day of
follow-up on a monthly basis. Patients who died from
other diseases were normalized as a loss to follow-up.
Recurrence rates were compared by the log-rank test.
P < 0.05 was used to indicate statistical significance. The
factors found to have a significant impact on postopera-
tive recurrence of cervical cancer based on univariate
analysis were entered into a Cox proportional hazards
regression model for multivariate analysis.
Results
Clinical data of postoperative recurrence
All 424 patients enrolled in this study experienced surgi-
cal treatment, and recurrence occurred in 23 cases. The
median recurrence time was 15.54 months (range, 12.5
to 48 months).
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recurrence
Univariate risk analysis was performed first (Table 2). Data
showed that tumor histological grade (P < 0.001) and clin-
ical stage (P < 0.001) were well correlated with cervical
cancer recurrence after surgery. Patients with moderately
and highly differentiated cancer or ≤ IB stage cancer were
subject to lower recurrence rates when compared to
patients with poorly differentiated cancer or > IB stage
cancer, respectively. Furthermore, the recurrence rate was
significantly higher in patients with positive pelvic lymph
nodes (16.038%) than in patients with negative pelvic
lymph nodes (1.887%, P < 0.001). Tumor recurrence oc-
curred more frequently in patients without postoperative
chemotherapy and radiotherapy than in patients with
postoperative chemotherapy (P = 0.007) or radiotherapy
(P = 0.000), but there was no significant difference in
recurrence between patients with preoperative adjuvant
therapy and those without preoperative adjuvant ther-
apy (P = 0.597). The recurrence rate was not associated
with the pathological type of cancer (that is, no signifi-
cant difference existed between patients with squamous
carcinoma and patients with adenocarcinoma or othersTable 2 Univariate analysis of clinicopathological factors for c
Factor Total number (n) Recurre
Age (years)
≤ 40 57 1
> 40 367 22
Pathological type
Squamous carcinoma 328 20
Adenocarcinoma and others 96 3
Histological grade
Poorly differentiated 246 21
Moderately or highly differentiated 178 2
Clinical stage
≤ IB 224 2












Without 64 7(P = 0.275)). The age of the patient also did not affect
the recurrence rate (P = 0.179).
Multivariate analysis of clinicopathological factors for
recurrence
All the single risk factors affecting postoperative recur-
rence rate were further studied using COX proportional
hazards regression model. Histological grade, clinical
stage, postoperative radiotherapy, postoperative chemo-
therapy and postoperatively confirmed positive lymph
node were included in this model to find out which risk
factors were vital for recurrence by forward stepwise
regression on the level of α = 0.05. The results (Table 3)
revealed that postoperatively confirmed positive lymph
nodes (degree of risk, 14.649; 95% CI 1.781 to 120.520;
P = 0.013) and postoperative chemotherapy (degree of
risk, 0.252; 95% CI 0.074 to 0.856; P = 0.027) were
significant independent predictors of cervical cancer
recurrence.
Discussion
Radical hysterectomy with lymphadenectomy is the rou-
tine treatment for early (FIGO IB-IIA) invasive cervicalervical cancer recurrence after surgery





























Upper limit Lower limit
Lymph node
(positive or negative)
2.684 1.075 6.233 1 0.013 14.649 1.781 120.520
Postoperative radiotherapy −0.717 0.597 1.440 1 0.230 0.488 0.151 1.575
Postoperative chemotherapy −1.379 0.624 4.884 1 0.027 0.252 0.074 0.856
Histological grade −0.913 0.790 1.335 1 0.248 0.401 0.085 1.889
Clinical stage 0.265 0.842 0.099 1 0.753 1.303 0.250 6.787
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cured. However, long-term prognosis is poor due to the
high rate of recurrence. Many factors have been reported
to have an impact on cervical cancer recurrence. In the
current study, we evaluated the clinicopathological
factors in 424 patients with stage IB to IIA cervical can-
cer who underwent surgical treatment and found that
the clinical stage, histological grade, pelvic lymph node,
postoperative radiotherapy and postoperative chemo-
therapy were significantly related to recurrence. Further-
more, pelvic lymph node metastasis and postoperative
chemotherapy were two independent risk factors for
recurrence based on multivariate analysis.
Lymph node metastasis is recognized as an unfavor-
able factor of cancer recurrence [8,9]. Positive lymph
node also indicates poor prognosis in cervical cancer in
that the survival rates for patients with lymph node me-
tastases are significantly lower than those for patients
with no detectable nodal metastases [10,11]. Girardi and
colleagues [12] revealed that the recurrence rate was
higher when the parametrial nodes were positive than
when they were negative. Similarly, univariate and multi-
variate analyses in our study showed that the recurrence
rate with lymph node metastasis was 14.69 times more
than that without lymph node metastasis. Therefore,
lymph node metastasis has potential prognostic value
and systematic lymphadenectomy plays a vital role in
the treatment for node-positive patients.
In addition to lymph node metastasis, the clinical stage
and tumor differentiation degree were also demonstrated
to be closely associated with cervical recurrence [13,14].
Our data showed a worse prognosis in lower differen-
tiated cervical cancer patients compared with well-
differentiated cervical cancer patients, with recurrence
rates of 8.537% and 1.124%, respectively. Patients with
lower stage cancer (≤ IB stage) were subject to lower
recurrence rates when compared to patients with ad-
vanced cancer (> IB stage).
There are different opinions as to whether neoadjuvant
therapy, especially neoadjuvant chemotherapy, can pro-
long patient survival time and reduce the relapse rate.
Some clinical studies have shown that neoadjuvant
chemotherapy can further reduce the tumor volume,improve the outcome of surgical treatment, and eventu-
ally give a better prognosis. Chen and colleagues [15]
reported that, compared to the surgery group alone,
3-year and 5-year survival rates of interventional neoad-
juvant chemotherapy combined with surgery are sig-
nificantly improved (P < 0.05). However, some other
researchers deny the conclusion that neoadjuvant
chemotherapy can reduce recurrence and improve long-
term survival [16]. Our results showed that the re-
currence rate was not significantly different between
patients with and without preoperative adjuvant therapy.
Currently, a majority of studies show that postopera-
tive radiotherapy and chemotherapy have a good effect
on preventing recurrence and improving prognosis
in cervical cancer patients, especially for patients with
pelvic lymph node metastases. Kukura and colleagues
[17] confirmed the importance of whole pelvic radiother-
apy by analysis of 72 stage IB cervical cancer patients.
Yamakawa and colleagues [18] presented a significantly
decreased recurrence rate with postoperative radiotherapy
plus chemotherapy compared to those without adjuvant
treatment. Liu and colleagues [19] showed that there was
a higher survival rate in patients with stage IB and IIA
carcinoma of the cervix who received adjuvant chemora-
diotherapy after radical hysterectomy than those undergo-
ing radical hysterectomy alone. Rotman and colleagues
[20] confirmed that pelvic radiotherapy after radical sur-
gery can significantly reduce the risk of recurrence and
prolong progression-free survival in women with stage IB
cervical cancer. In our study, 179 of 256 patients received
postoperative radiotherapy and had a recurrence rate of
4.469%, whereas the recurrence rate in those without
radiotherapy was 15.584%. There was a significant differ-
ence between these two groups (P = 0.000). Among 246
patients that needed further postoperative chemotherapy,
182 patients with postoperative chemotherapy had a re-
currence rate of 2.747% while 64 patients without chemo-
therapy had a recurrence rate of 10.93% (P = 0.007).
Besides the univariate analysis, postoperative chemother-
apy displayed a potential prognostic value for cervical
cancer recurrence through the multivariate analysis.
In the multivariate COX proportional hazards regres-
sion model analysis, clinical stage, histological grade and
Wang et al. World Journal of Surgical Oncology 2013, 11:301 Page 5 of 5
http://www.wjso.com/content/11/1/301postoperative radiotherapy did not show a statistically
significant difference, though each factor alone showed
statistical difference in the single factor analysis. The
reason may be that the effect of each factor in single
factor analysis could be overlapped by the combined
effects of several other factors in COX multivariate
analysis, or that its role could be replaced by other risk
factors. However, in spite of very few clinical reports
showing agreement, our data showed postoperative
chemotherapy alone is an independent factor for the
recurrence of cervical cancer. This result is likely due to
the long follow-up time, with the role of chemotherapy
manifesting gradually with the extension of follow-up.
Of course, larger sample and multicenter prospective
studies are needed to validate this result.
Conclusion
Based on the findings of this study, we conclude that a
positive lymph node is an important indicator for recur-
rence of cervical cancer after radical surgery. Surgeons
should pay attention to lymph node resection in the surgi-
cal treatment of node-positive patients. At the same time,
we advocate the application of postoperative chemother-
apy for special patients, which is beneficial to reduce the
recurrence of cervical cancer.
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